Astria Therapeutics shares are trading higher after the company reported Q2 financial results. Also, Oppenheimer maintained an Outperform rating on the stock and raised its price target from $25 to $26.
Portfolio Pulse from Benzinga Newsdesk
Astria Therapeutics shares are trading higher following the release of their Q2 financial results. Oppenheimer has maintained an Outperform rating on the stock and raised its price target from $25 to $26.
August 13, 2024 | 2:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Astria Therapeutics shares are trading higher after the company reported Q2 financial results. Oppenheimer maintained an Outperform rating and raised its price target from $25 to $26.
The positive Q2 financial results and the increased price target from a reputable analyst firm like Oppenheimer are likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100